These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30761741)

  • 1. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.
    Wang Z; Jiang J; Qin T; Xiao Y; Han L
    J Cell Mol Med; 2019 Apr; 23(4):2678-2688. PubMed ID: 30761741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sonic Hedgehog-GLI Family Zinc Finger 1 Signaling Pathway Promotes the Growth and Migration of Pancreatic Cancer Cells by Regulating the Transcription of Eukaryotic Translation Initiation Factor 5A2.
    Xu X; Liu H; Zhang H; Dai W; Guo C; Xie C; Wei S; He S; Xu X
    Pancreas; 2015 Nov; 44(8):1252-8. PubMed ID: 26465952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway.
    Han L; Jiang J; Ma Q; Wu Z; Wang Z
    Int J Oncol; 2018 Jun; 52(6):2101-2109. PubMed ID: 29620188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
    J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway.
    Ma H; Kong L; Liu L; Du Y; Zhu X; Wang J; Zhao W
    Mol Carcinog; 2024 Jul; 63(7):1221-1234. PubMed ID: 38517039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.
    Yu S; Wang M; Zhang H; Guo X; Qin R
    J Cell Mol Med; 2024 Jun; 28(12):e18444. PubMed ID: 38924205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway.
    Zhuang L; Yao Y; Peng L; Cui F; Chen C; Zhang Y; Sun L; Yu Q; Lin K
    Dig Dis Sci; 2022 Aug; 67(8):3773-3782. PubMed ID: 34623580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
    Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
    Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
    Yao N; Chen Q; Shi W; Tang L; Fu Y
    Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of
    Wang X; Su W; Qin C; Gao R; Shao S; Xu X; Zhang Z; Gao J
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):269. PubMed ID: 39082329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance.
    Xu M; Li L; Liu Z; Jiao Z; Xu P; Kong X; Huang H; Zhang Y
    Cancer Lett; 2013 Jun; 333(2):152-8. PubMed ID: 23340176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
    Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
    Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
    Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
    Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R
    Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
    Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P
    Oncotarget; 2017 Feb; 8(6):9216-9229. PubMed ID: 27999205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.